Clinical trials: ITP Immune-Mediated Thrombocytopenia
ITP - Immune Thrombocytopenia
Immune Markers in Pediatric ITP on Second Line Therapy
Immune thrombocytopenia (ITP) is a common autoimmune disease characterized by low platelet count and increased risk of bleeding.
- Trial name
- NCT06093529
- Testing
- complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.
- Volunteers
- 42 people
- Sponsor
- Assiut University
AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
OM336 in Autoimmune Cytopenias
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
- Conditions
- AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
- Trial name
- NCT07083960
- Testing
- OM336
- Where
- 7 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Lakefront Biotherapeutics West LLC
ITP - Immune Thrombocytopenia
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
- Trial name
- NCT07093606
- Testing
- Eltrombopag
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Immune Mediated Anemia, Immune Mediated Thrombocytopenia
Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias
Background: People who have a blood stem cell transplant can sometimes develop cytopenia. This means that their levels of one or more types of blood cell, such as the red cells or platelets, are lower than they should be.
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Trial name
- NCT05509582
- Testing
- fostamatinib
- Where
- United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
ITP - Immune Thrombocytopenia
"Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children"
the investigators aim in this study to investigate the potential association of single gene polymorphisms of CTLA-4 (SNPs; rs: 3087243) using real-time PCR in children with primary ITP.
- Trial name
- ITP (NCT07014904)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
TGD001 Treatment in Thrombotic Microangiopathies
This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or…
- Trial name
- NCT07459114
- Testing
- TGD001
- Volunteers
- 70 people
- Sponsor
- TargED Biopharmaceuticals B.V.
ITP - Immune Thrombocytopenia
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and…
- Trial name
- Ava dosing (NCT07133659)
- Testing
- Avatrombopag 20 mg Oral Tablet
- Where
- Iraq
- Volunteers
- 25 people
- Sponsor
- Al-Mustansiriyah University
ITP - Immune Thrombocytopenia
Explore the Relationship Between Platelet Count and Bleeding Score in ITP
Assessment of bleeding scores in immune thrombocytopenia purpuria to explore the relationship between platelet count and bleeding score in immune thrombocytopenia purpura (ITP) and compare the clinical practicability of bleeding…
- Trial name
- NCT06273956
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
ITP - Immune Thrombocytopenia
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
This study is an open label, randomized controlled, multicenter clinical trial aimed at comparing the efficacy and safety of the combination of atorvastatin and all trans retinoic acid with atorvastatin alone in the treatment of…
- Trial name
- NCT07278908
- Testing
- Avatrombopag+All trans retinoic acid, Avatrombopag
- Volunteers
- 248 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
ITP - Immune Thrombocytopenia, Primary Immune Thrombocytopenia (ITP)
RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia
Primary immune thrombocytopenia (PIT), previously referred to as idiopathic thrombocytopenic purpura, is an acquired disease characterized by accelerated platelet destruction and deficient platelet production by megakaryocytes.
- Trial name
- RESTI (NCT06919341)
- Where
- 36 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundación Española de Hematología y Hemoterapía
ITP - Immune Thrombocytopenia, Chronic ITP
Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP
This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.
- Conditions
- ITP - Immune Thrombocytopenia, Chronic ITP, Refractory ITP
- Trial name
- NCT05613296
- Testing
- Fostamatinib
- Where
- 21 sites in Italy
- Volunteers
- 95 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
ITP - Immune Thrombocytopenia
Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
This study is a clinical study initiated by single-arm, single-center, multiple administration researchers. The main purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells in refractory ITP…
- Trial name
- MSC、ITP (NCT06813157)
- Testing
- MSC
- Where
- China
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
ITP - Immune Thrombocytopenia
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
This prospective, single-arm, multicenter, exploratory study will enroll 38 adults patients with newly diagnosed primary immune thrombocytopenia (ITP).
- Trial name
- NCT07788456
- Testing
- standard-dose methylprednisolone/prednisone., thrombopoietin receptor agonist(TPO-RA), including but not limited to hetrombopag or eltrombopag., rituximab.
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
ITP - Immune Thrombocytopenia
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
This study aims to evaluate the efficacy and safety of Ripertamab in combination with Eltrombopag compared to Eltrombopag alone for patients with Primary Immune Thrombocytopenia (ITP) who have not responded to or have relapsed…
- Trial name
- RPE-ITP (NCT06790888)
- Testing
- Ripertamab/Eltrombopag, Eltrombopag
- Volunteers
- 78 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
This single-arm, open-label exploratory trial aims to evaluate the safety, feasibility, and preliminary efficacy of RN1201 Injection in patients with antibody-mediated diseases, including refractory immune-mediated platelet…
- Trial name
- NCT07072247
- Testing
- CD19 and BCMA-targeted allogeneic CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary…
- Conditions
- Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
- Trial name
- NCT07549698
- Testing
- CTX112
- Where
- 12 sites in United States, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- CRISPR Therapeutics AG
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
ITP - Immune Thrombocytopenia
TPO-RA Plus Baricitinib vs. TPO-RA for ITP
This is a prospective, randomized, controlled trial. ITP patients who failed prior full-does TPO-RA monotheray for 14 days. Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus TPO-RA or TPO-RA alone.
- Trial name
- NCT07669675
- Testing
- Baricitinib, TPO-RA
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
ITP - Immune Thrombocytopenia
Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura
1. Assesement of response to Thrombopoietin receptor agonists (TPO-RAs) as treatment in Idiopathic thrombocytopenia purpura patients in Assiut University hospital. 2.
- Trial name
- NCT06137105
- Testing
- eltrombopag and romiplastim
- Volunteers
- 100 people
- Sponsor
- Assiut University
Immune Thrombocytopenia, Blood Platelet Disorder
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
- Conditions
- Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic
- Trial name
- NCT06291415
- Testing
- HMPL-523
- Where
- 28 sites in United States, Australia and 3 more
- Sponsor
- Hutchmed